Compare HXHX & ABP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HXHX | ABP |
|---|---|---|
| Founded | 2003 | 2004 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.0M | 12.5M |
| IPO Year | 2025 | N/A |
| Metric | HXHX | ABP |
|---|---|---|
| Price | $0.51 | $3.50 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 17.4M | 10.7K |
| Earning Date | 02-18-2026 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1.80 | N/A |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $34,088,144.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.69 | ★ N/A |
| Revenue Growth | 32.57 | ★ 50.00 |
| 52 Week Low | $0.33 | $3.56 |
| 52 Week High | $6.29 | $42.90 |
| Indicator | HXHX | ABP |
|---|---|---|
| Relative Strength Index (RSI) | 43.88 | 32.76 |
| Support Level | $0.47 | $3.82 |
| Resistance Level | $0.62 | $4.11 |
| Average True Range (ATR) | 0.10 | 0.40 |
| MACD | -0.01 | -0.08 |
| Stochastic Oscillator | 5.73 | 5.93 |
Haoxin Holdings Ltd is engaged in the logistics industry, including container provider of temperature-controlled truckload service and urban delivery services in China, freight forwarding, cold chain transportation and other businesses. The types of goods involved are all kinds of new energy materials that require low temperature, heat preservation, and constant temperature, electronic products, medicines, meat, fruits, vegetables and others.
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms. The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with pharmaceutical and research institutions.